Judge Pauses Invalidation Of Patent For Janssen's Zytiga

Law360 (October 31, 2018, 4:51 PM EDT) -- A New Jersey federal judge on Tuesday paused his Friday order that invalidated a patent covering Janssen Biotech Inc.'s blockbuster oncology medication Zytiga, allowing the company to appeal the opinion to the Federal Circuit.

U.S. District Judge Kevin McNulty entered an injunction staying the effectiveness of his Oct. 26 order for the earlier of either midnight on Nov. 9 or when the Federal Circuit issues a decision on a petition for a stay pending appeal, according to Tuesday's order.

"Plaintiff shall not enter into any binding offer for an authorized generic while this order is in effect," reads a handwritten portion...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!